<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d518" origId="Acebutolol"><sentence id="DrugDDI.d518.s0" origId="s0" text="Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents."><entity id="DrugDDI.d518.s0.e0" origId="s0.p0" charOffset="24-29" type="drug" text="drugs"/><entity id="DrugDDI.d518.s0.e1" origId="s0.p1" charOffset="39-48" type="drug" text="reserpine"/><entity id="DrugDDI.d518.s0.e2" origId="s0.p7" charOffset="94-113" type="drug" text="beta-blocking agent"/><pair id="DrugDDI.d518.s0.p0" e1="DrugDDI.d518.s0.e0" e2="DrugDDI.d518.s0.e1" interaction="?"/><pair id="DrugDDI.d518.s0.p1" e1="DrugDDI.d518.s0.e0" e2="DrugDDI.d518.s0.e2" interaction="?"/><pair id="DrugDDI.d518.s0.p2" e1="DrugDDI.d518.s0.e1" e2="DrugDDI.d518.s0.e2" interaction="?"/></sentence><sentence id="DrugDDI.d518.s1" origId="s1" text="Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia."><entity id="DrugDDI.d518.s1.e0" origId="s1.p10" charOffset="22-32" type="drug" text="acebutolol"/></sentence><sentence id="DrugDDI.d518.s2" origId="s2" text="Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops."><entity id="DrugDDI.d518.s2.e0" origId="s2.p38" charOffset="79-105" type="drug" text="beta-adrenergic antagonist"/><entity id="DrugDDI.d518.s2.e1" origId="s2.p40" charOffset="128-138" type="drug" text="stimulants"/><pair id="DrugDDI.d518.s2.p0" e1="DrugDDI.d518.s2.e0" e2="DrugDDI.d518.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d518.s3" origId="s3" text="Patients receiving beta-blockers should be warned of this potential hazard."><entity id="DrugDDI.d518.s3.e0" origId="s3.p49" charOffset="19-33" type="drug" text="beta-blockers"/></sentence><sentence id="DrugDDI.d518.s4" origId="s4" text="Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported."><entity id="DrugDDI.d518.s4.e0" origId="s4.p55" charOffset="16-32" type="drug" text="antihypertensive"/><entity id="DrugDDI.d518.s4.e1" origId="s4.p56" charOffset="43-75" type="drug" text="beta-adrenoceptor blocking agent"/><entity id="DrugDDI.d518.s4.e2" origId="s4.p57" charOffset="80-116" type="drug" text="nonsteroidal anti-inflammatory drugs"/><pair id="DrugDDI.d518.s4.p0" e1="DrugDDI.d518.s4.e0" e2="DrugDDI.d518.s4.e1" interaction="?"/><pair id="DrugDDI.d518.s4.p1" e1="DrugDDI.d518.s4.e0" e2="DrugDDI.d518.s4.e2" interaction="?"/><pair id="DrugDDI.d518.s4.p2" e1="DrugDDI.d518.s4.e1" e2="DrugDDI.d518.s4.e2" interaction="?"/></sentence><sentence id="DrugDDI.d518.s5" origId="s5" text="No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed."><entity id="DrugDDI.d518.s5.e0" origId="s5.p62" charOffset="33-40" type="drug" text="digoxin"/><entity id="DrugDDI.d518.s5.e1" origId="s5.p63" charOffset="42-61" type="drug" text="hydrochlorothiazide"/><entity id="DrugDDI.d518.s5.e2" origId="s5.p64" charOffset="63-74" type="drug" text="hydralazine"/><entity id="DrugDDI.d518.s5.e3" origId="s5.p65" charOffset="76-90" type="drug" text="sulfinpyrazone"/><entity id="DrugDDI.d518.s5.e4" origId="s5.p66" charOffset="92-111" type="drug" text="oral contraceptives"/><entity id="DrugDDI.d518.s5.e5" origId="s5.p67" charOffset="113-124" type="drug" text="tolbutamide"/><entity id="DrugDDI.d518.s5.e6" origId="s5.p69" charOffset="129-137" type="drug" text="warfarin"/><pair id="DrugDDI.d518.s5.p0" e1="DrugDDI.d518.s5.e0" e2="DrugDDI.d518.s5.e1" interaction="?"/><pair id="DrugDDI.d518.s5.p1" e1="DrugDDI.d518.s5.e0" e2="DrugDDI.d518.s5.e2" interaction="?"/><pair id="DrugDDI.d518.s5.p2" e1="DrugDDI.d518.s5.e0" e2="DrugDDI.d518.s5.e3" interaction="?"/><pair id="DrugDDI.d518.s5.p3" e1="DrugDDI.d518.s5.e0" e2="DrugDDI.d518.s5.e4" interaction="?"/><pair id="DrugDDI.d518.s5.p4" e1="DrugDDI.d518.s5.e0" e2="DrugDDI.d518.s5.e5" interaction="?"/><pair id="DrugDDI.d518.s5.p5" e1="DrugDDI.d518.s5.e0" e2="DrugDDI.d518.s5.e6" interaction="?"/><pair id="DrugDDI.d518.s5.p6" e1="DrugDDI.d518.s5.e1" e2="DrugDDI.d518.s5.e2" interaction="?"/><pair id="DrugDDI.d518.s5.p7" e1="DrugDDI.d518.s5.e1" e2="DrugDDI.d518.s5.e3" interaction="?"/><pair id="DrugDDI.d518.s5.p8" e1="DrugDDI.d518.s5.e1" e2="DrugDDI.d518.s5.e4" interaction="?"/><pair id="DrugDDI.d518.s5.p9" e1="DrugDDI.d518.s5.e1" e2="DrugDDI.d518.s5.e5" interaction="?"/><pair id="DrugDDI.d518.s5.p10" e1="DrugDDI.d518.s5.e1" e2="DrugDDI.d518.s5.e6" interaction="?"/><pair id="DrugDDI.d518.s5.p11" e1="DrugDDI.d518.s5.e2" e2="DrugDDI.d518.s5.e3" interaction="?"/><pair id="DrugDDI.d518.s5.p12" e1="DrugDDI.d518.s5.e2" e2="DrugDDI.d518.s5.e4" interaction="?"/><pair id="DrugDDI.d518.s5.p13" e1="DrugDDI.d518.s5.e2" e2="DrugDDI.d518.s5.e5" interaction="?"/><pair id="DrugDDI.d518.s5.p14" e1="DrugDDI.d518.s5.e2" e2="DrugDDI.d518.s5.e6" interaction="?"/><pair id="DrugDDI.d518.s5.p15" e1="DrugDDI.d518.s5.e3" e2="DrugDDI.d518.s5.e4" interaction="?"/><pair id="DrugDDI.d518.s5.p16" e1="DrugDDI.d518.s5.e3" e2="DrugDDI.d518.s5.e5" interaction="?"/><pair id="DrugDDI.d518.s5.p17" e1="DrugDDI.d518.s5.e3" e2="DrugDDI.d518.s5.e6" interaction="?"/><pair id="DrugDDI.d518.s5.p18" e1="DrugDDI.d518.s5.e4" e2="DrugDDI.d518.s5.e5" interaction="?"/><pair id="DrugDDI.d518.s5.p19" e1="DrugDDI.d518.s5.e4" e2="DrugDDI.d518.s5.e6" interaction="?"/><pair id="DrugDDI.d518.s5.p20" e1="DrugDDI.d518.s5.e5" e2="DrugDDI.d518.s5.e6" interaction="?"/></sentence></document>